GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensysce Biosciences Inc (NAS:ENSC) » Definitions » Operating Margin %

Ensysce Biosciences (Ensysce Biosciences) Operating Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ensysce Biosciences Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Ensysce Biosciences's Operating Income for the three months ended in Mar. 2024 was $-1.84 Mil. Ensysce Biosciences's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Ensysce Biosciences's Operating Margin % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Ensysce Biosciences's Operating Margin % or its related term are showing as below:


ENSC's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -155.555
* Ranked among companies with meaningful Operating Margin % only.

Ensysce Biosciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Ensysce Biosciences's Operating Income for the three months ended in Mar. 2024 was $-1.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.00 Mil.

Warning Sign:

Ensysce Biosciences Inc has never been profitable in the past 3 years. It lost money every year.


Ensysce Biosciences Operating Margin % Historical Data

The historical data trend for Ensysce Biosciences's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensysce Biosciences Operating Margin % Chart

Ensysce Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Operating Margin %
- - - -

Ensysce Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ensysce Biosciences's Operating Margin %

For the Biotechnology subindustry, Ensysce Biosciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensysce Biosciences's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Ensysce Biosciences's Operating Margin % falls into.



Ensysce Biosciences Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ensysce Biosciences's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-10.718 / 0
= %

Ensysce Biosciences's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-1.843 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ensysce Biosciences  (NAS:ENSC) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Ensysce Biosciences Operating Margin % Related Terms

Thank you for viewing the detailed overview of Ensysce Biosciences's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensysce Biosciences (Ensysce Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.
Executives
Bob G Gower director 402 TIMBERWILDE LANE, HOUSTON TX 77024
Lynn Kirkpatrick director, officer: Chief Executive Officer 110 110TH AVENUE NE, SUITE 685, BELLEVUE WA 98004
Nilab Osman officer: Chief Medical Officer C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Lee M. Rauch director C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Linda Pestano officer: Chief Development Officer 7946 IVANHOE AVENUE, LA JOLLA CA 92037
Kevin Geoffrey Birkett officer: Chief Commercial Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
William K Schmidt officer: Chief Medical Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
David Carl Humphrey officer: Chief Financial Officer 4767 NEXUS CENTRE DR, SAN DIEGO CA 92121
William H Chang director, 10 percent owner C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Andrew Benton director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Adam Levin director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Jeffrey Millard officer: Chief Operating Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Richard Chester Wright officer: Chief Business Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Steven Robert Martin director 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Curtis Rosebraugh director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037